AbbVie (NYSE:ABBV) Updates Q4 2025 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its fourth quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.320-3.360 for the period, compared to the consensus estimate of 3.360. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.610-10.650 EPS.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $220.06 on Friday. The firm has a 50 day simple moving average of $226.59 and a 200 day simple moving average of $215.12. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market cap of $388.93 billion, a PE ratio of 166.71, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the company posted $3.00 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts predict that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s payout ratio is presently 496.97%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ABBV shares. Morgan Stanley increased their price objective on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. UBS Group initiated coverage on shares of AbbVie in a research report on Wednesday. They set a “neutral” rating and a $240.00 price objective on the stock. Scotiabank assumed coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $246.89.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently modified their holdings of the company. Paces Ferry Wealth Advisors LLC boosted its holdings in shares of AbbVie by 3.0% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 2,303 shares of the company’s stock worth $533,000 after buying an additional 67 shares during the period. Brogan Financial Inc. raised its holdings in AbbVie by 2.5% in the 3rd quarter. Brogan Financial Inc. now owns 3,090 shares of the company’s stock worth $715,000 after acquiring an additional 74 shares during the period. Rakuten Securities Inc. lifted its position in AbbVie by 26.5% during the 2nd quarter. Rakuten Securities Inc. now owns 368 shares of the company’s stock worth $68,000 after acquiring an additional 77 shares during the last quarter. Yukon Wealth Management Inc. boosted its holdings in AbbVie by 4.8% during the third quarter. Yukon Wealth Management Inc. now owns 1,693 shares of the company’s stock valued at $392,000 after acquiring an additional 77 shares during the period. Finally, Parvin Asset Management LLC grew its position in shares of AbbVie by 2.4% in the third quarter. Parvin Asset Management LLC now owns 4,862 shares of the company’s stock valued at $1,126,000 after purchasing an additional 112 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.